Skip to main content
Premium Trial:

Request an Annual Quote

Accelrys to Acquire Synomics

NEW YORK, June 21 - Accelrys announced it will acquire Synomics in a stock transaction valued at $4 million, the companies announced Thursday.

Accelrys, based in San Diego and Cambridge, UK, and a subsidiary of Pharmacopeia of Princeton, NJ, agreed to acquire all outstanding stock of privately-held Synomics. The companies believe the transaction will be completed within several days. 

"The acquisition of Synomics marks another significant step towards the development by Accelrys of a comprehensive, integrated software platform for research and development," Michael Stapleton, chief operating officer of Accelrys, said in a statement. "In addition to strengthening our strategic technology position, the acquisition will provide us with 40 highly qualified staff who will be quickly integrated, primarily into our new consulting organization."

Stapleton added that the acquisition may "slightly dilute" Accelry's earnings for the remainder of 2001 as the company integrates Synomics software into its own technology and its sales and marketing network.

Synomics, a developer of enterprise-wide software systems, is based in Cambridge, UK.

Accelrys was formed in April when Pharmacopeia merged its software subsidiaries. 

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.